1384984-28-4

Basic information

• Product Name: 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol
• Synonyms: 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol
• CAS NO: 1384984-28-4
• Molecular Weight: 362.361
• Mol File: 1384984-28-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(1384984-28-4)
• EPA Substance Registry System: 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(1384984-28-4)

Safety Data

• Hazardous Substances Data: 1384984-28-4(Hazardous Substances Data)

Usage

Core Structure

Pyrimidine

Ring Structure

Tetrahydrofuran

Functional Groups

Amino group, Fluorine atom, Nitro group

Attached Moiety

Propan-2-ol
Potential pharmacological properties
Applications in pharmaceutical research and drug development
Further investigation needed for specific biological activity and potential medical uses.

Upstream product

• 1319255-87-2 2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)propan-2-ol 
• 1384984-27-3 4-bromo-3-fluoro-6-nitro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-24-0 3-fluoro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-25-1 4-bromo-3-fluoro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-26-2 N-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoro-acetamide 
• 1384984-22-8 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran 
• 59255-94-6 2-bromo-3-fluoronitrobenzene 

Downstream Products

• 1384984-29-5 2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol 
• 1384984-18-2 (+)-(R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea 

Relevant articles and documents

SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[D]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF

The invention relates to solid forms of the Formula (I) wherein X is -PO(OH)2, -PO(OH)O-M+, or -PO(O-)2?2M+,wherein M is a monovalent cation such as Na+, K+, Li+, or NH4+. The invention also provides pharmaceutically acceptable compositions comprising the solid form of he compound and method of using the compositions in the treatment of various disorders.

COMBINATION THERAPY COMPRISING|1 -ETHYL-3-[5-[2-{1 -HYDROXY-1 -METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRA HYDROFURAN-2-|YL}-1 H-BENZIMIDAZOL-2-YL]UREA AND DERIVATIVES THEREOF TO TREAT MYCOBACTERIUM|DISEASES

The present invention relates to combination therapies comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhi

SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA

The present application is directed to solid forms of compounds of formula I: and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.